Patent Application
20140363841
The present invention relates to the field of screening agents, such as for drug development. In particular, the method relates to a method of screening of agents as drug candidates using induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cells. The present invention also relates to iPSC-derived cardiomyocyte-like cells for predicting risk and/or predisposition to cardiac arrhythmia in a subject.
Cardiovascular disease is a major cause of morbidity and mortality worldwide and the development of cardiovascular agents requires elaborate safety screening. In addition, cardiotoxicity is an important aspect to consider during the development of both cardiovascular and non-cardiovascular agents. The effect of non-cardiovascular agents on the cardiovascular system can impact on the therapeutic use of such agents. For example, both cardiovascular and non-cardiovascular agents have been withdrawn from the market due to their cardiotoxic effects. Current drug discovery and development programs are inefficient as more than 90% of the lead molecules identified by in vitro screening systems fail to become drugs due to safety and efficacy issues in clinical applications. It is therefore desirable to improve on screening methods of agents as drug candidates.
The present invention provides a method for screening an agent as a drug candidate, comprising the steps of:
(i) contacting at least one induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell with the agent at different dosages; and
(ii) determining the effect of the agent based on changes in at least one electrophysiological property of the iPSC-derived cardiomyocyte-like cell contacted with different dosages of the agent compared to a control comprising at least one iPSC-derived cardiomyocyte-like cell absent the agent.
In a second aspect, the present invention provides a method for predicting risk of and/or predisposition to cardiac arrhythmia in a subject, comprising:
(i) providing at least one induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell derived from the subject;
(ii) contacting the at least one iPSC-derived cardiomyocyte-like cell with a beta-adrenergic agonist;
(iii) further contacting the at least one iPSC-derived cardiomyocyte-like cell from (ii) with a beta-blocker;
(iv) determining a first Beat Rate Variability for the at least one iPSC-derived cardiomyocyte-like cell based on changes in at least one electrophysiological property in the at least one iPSC-derived cardiomyocyte-like cell; and
(v) comparing the first Beat Rate Variability to a second Beat Rate Variability for at least one control.
The term “cardiomyocyte-like cell” is intended to mean a cell sharing features with a cardiomyocyte. Cardiomyocyte-like cells are further defined by morphological characteristics as well as by specific marker characteristics. As induced pluripotent stem cell-derived cardiomyocyte-like cells share similar characteristics (including marker and electrophysiological characteristics) with cardiomyocytes, induced pluripotent derived cardiomyocyte-like cells may be used interchangeably with induced pluripotent stem cell-derived cardiomyocytes.
Cardiovascular agent refers to agents that have potential to ameliorate, control, eliminate, prevent, reduce and/or treat a wide variety of disorders related to the heart and/or circulation.
Conduction velocity refers to the speed at which cardiomyocytes propagate an electrical impulse across cardiac tissue or syncytium.
An “embryoid body” refers to an aggregate of cells derived from pluripotent cells, where cell aggregation can be initiated by any method that prevents the cells from adhering to a surface to form typical colony growth.
FPD or field potential duration corresponds to the action potential duration, which can be correlated to a QT interval in an electrocardiogram. It is measured from minimum of the Na+ peak to the maximum/minimum of the IKr current peak.
FPmin corresponds to maximal negative amplitude of field potential that depends on critically on the current through voltage dependent Na+-channels
As used herein, the term “induced pluripotent stem cells” refers to a pluripotent stem cell derived from a somatic cell (e.g. an adult somatic cell). Induced pluripotent stem cells are similar to embryonic stem cells in their differentiation abilities to form any adult cell types, but are not derived from an embryo.
As used herein, the term “pluripotent” refers to the potential of a stem cell to make any differentiated cell type of an organism. Pluripotent stem cells can give rise to any fetal or adult cell type. However, alone they cannot develop into a fetal or adult organism because they lack the potential to contribute to extraembryonic tissue, such as the placenta.
As used herein, the terms “Heart Rate Variability” (HRV) and “Beat Rate Variability” (BRV) are used interchangeably to refer to the physiological phenomenon of variation in the time interval between periodic changes in at least one electrophysiological property, for example between heartbeats in a beating heart, or the beat-to-beat interval. When measured on a beating heart, Beat Rate Variability refers to Heart Rate Variability. BRV may be measured using various methods including ECG, blood pressure, ballistocardiograms, the pulse wave signal derived from a photoplethysmograph, the power spectral density of beat-to-beat or RR intervals, field potential duration (FPD), minimum field potential (FPmin), conduction velocity, beating frequency and/or regularity of beating rhythm, and other methods known in the art.
Cardiac arrhythmia (also commonly known as dysrhythmia or irregular heartbeat) is associated to a heartbeat that beats either too fast or too slow. The heartbeat may also beat regularly or irregularly. Cardiac arrhythmia comes from any of a large and heterogeneous group of conditions in which there is abnormal electrical activity in the heart.
“Risk of” and/or “predisposition to” cardiac arrhythmia in a subject, as used in this specification, refers to the probability that the subject has, or will develop, cardiac arrhythmia in the future or near future. For example, a subject may consider various options for treatment or take up various preventative measures if a subject predicts risk of cardiac arrhythmia as far in advance as possible. Risk of cardiac arrhythmia in a subject may be due to genetic and non-genetic factors, for example a family history of cardiac arrhythmia, scarring of heart tissue (such as from a heart attack), electrolyte imbalances in blood, coronary artery disease, or other risk factors. Accordingly, severity of this risk in a subject is determined in comparison to the probability of cardiac arrhythmia in control groups, for example a group of normal individuals (i.e. individuals without cardiac arrhythmia risk factors) and/or a group of individuals with cardiac arrhythmia or having risk factors for cardiac arrhythmia.
The invention provides a method for screening an agent as a drug candidate, comprising the steps of:
(i) contacting at least one induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell with the agent at different dosages; and
(ii) determining the effect of the agent based on changes in at least one electrophysiological property of the iPSC-derived cardiomyocyte-like cell contacted with different dosages of the agent compared to a control comprising at least one iPSC-derived cardiomyocyte absent the agent. The electrophysiological property includes the field potential duration (FPD), minimum field potential (FPmin), conduction velocity, beating frequency and/or regularity of beating rhythm and may be measured with a multielectrode array or patch-clamp. The more sophisticated planar patch-clamp systems which are potentially suited for high throughput screening may also be used.
Accordingly, the method may be used to determine if an agent causes an increase, decrease or no changes in the field potential duration (FPD) compared to the control. The method may also be used to determine if an agent causes an increase, decease or no changes in the minimum field potential (FPmin). The method may also be used to determine if an agent causes an increase, decrease or no changes in the conduction velocity compared to the control. The method may also be used to determine if an agent causes an increase, decrease or no changes in the beating frequency compared to the control. The method may also be used to determine if an agent causes a change or no changes in regularity of beating rhythm compared to the control.
The method may thus be used for screening a drug candidate. In particular, the method may be used to screen for an agent exerting an effect on cardiomyocytes. For example, the method may be used to screen for an agent exerting any one of the following effects:
(i) increasing the field potential duration (FPD) compared to the control.
(ii) decreasing the field potential duration (FPD) compared to the control.
(iii) increasing the minimum field potential (FPmin) compared to the control.
(iv) decreasing the minimum field potential (FPmin) compared to the control.
(v) increasing the beating frequency compared to the control.
(vi) decreasing the beating frequency compared to the control
(vii) increasing conduction velocity compared to the control
(viii) decreasing conduction velocity compared to the control; or
(ix) disrupting the regularity of rhythmic waveform compared to the control.
Correspondingly, the control refers to the relevant electrophysiological property of the iPSC-cardiomyocyte-like cell absent the agent.
Further, depending on the effect exhibited, the agent may be useful for ameliorating, controlling, eliminating, preventing, reducing and/or treating a cardiac condition and may be further tested. Accordingly, the method may screen for a cardiovascular agent, an agent affecting cardiac function and/or an agent for ameliorating, controlling, eliminating, preventing, reducing and/or reducing a cardiac condition. In particular, the method may be for screening anti-arrhythmic agents.
The present method may also be used for assessing the cardiotoxicty of the agent. For example, an agent may be considered cardiotoxic if the agent excessively exerts an effect on at least one iPSC-derived cardiomyocyte compared to the control. An agent may also be considered cardiotoxic if it increases or decreases at least one electrophysiological property to such an extent that it cannot be considered safe for use. For example, an agent that increases the field potential duration (FPD), minimum field potential (Fpmin), conduction velocity, and/or the beating frequency excessively is unlikely to be safe. Alternatively, an agent that decreases the field potential duration (FPD), minimum field potential, (Fpmin), conduction velocity and/or the beating frequency, excessively (for example, almost to a flat line) is unlikely to be safe. Further, an agent may also be considered cardiotoxic if it causes a change in the regularity of beating rhythm, for example an irregular beating rhythm. The cardiotoxicity of agents with therapeutic applications other than cardiovascular therapy (i.e. non-cardiovascular agents) may also be assessed.
Further, the method may be used for selecting a dosage and/or dosage range of the agent. The induced pluripotent stem cell-derived cardiomyocyte-like cell is a useful model to select for suitable dosage and/or dosage ranges. For example, the effect of various dosages of the agent is compared with said control and a suitable dosage or dosage range of the agent capable of exerting said effect may be selected. In particular, a suitable dosage and/or dosage range would be one exerts an effect likely to be therapeutically effective with minimal cardiotoxicity.
Induced pluripotent stem cells (iPSC) may be generated from adult somatic cells by any method, including but not limited to reprogramming to the embryonic state by viral or non-viral based methods. These iPSCs resemble embryonic stem cells in self renewal capacities and differentiation potential to various cell types including cardiomyocytes. For example, iPSCs may further be differentiated into cardiomycocyte-like cells by any method. Such induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cells (iPSC-CMs) were found to be a useful model for screening agents as drug candidates. According to a particular aspect, human induced pluripotent stem cells (hiPSCs) may be used to derive human induced pluripotent stem cell-derived cardiomyocyte-like cells (hiPSC-CMs).
The present invention is suitable for screening agents customised to an individual subject. Accordingly, cardiomyocyte-like cells derived from Induced pluripotent stem cells from said individual subject may be used in screening an agent for said individual subject. “Personalised medicine” is desired in the field of therapeutics and the present invention may be used to test variations in therapeutic effects of an agent for an individual.
Any suitable method may be used for preparing cardiomyocyte-like cells from induced pluripotent stem cell. For example, induced pluripotent stem cells may be generated by a process of reprogramming of somatic cells isolated from normal or diseased subjects. These hiPSC are then differentiated in vitro to cardiomyocytes. Accordingly, the induced pluripotent stem cell-derived cardiomyocyte-like cell(s) are already isolated (from the human or animal body). Accordingly, the method according to any aspect of the invention is performed in vitro.
The present invention also relates to Induced pluripotent stem cell (iPSC) derived cardiomyocyte-like cell(s) for use in screening an agent as a drug candidate.
Further, the invention also relates to Induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell(s) for use in a method according to any aspect of the invention. The invention also includes a kit comprising these induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell(s).
Moreover, the reduced BRV of hiPSC-CMs from individual with genetically predisposed arrhythmia further supported the feasibility of using such hiPSC-CMs to prognosticate cardiac arrhythmia. Accordingly, in a second aspect the present invention provides a method for predicting risk of and/or predisposition to cardiac arrhythmia in a subject, comprising:
(i) providing at least one induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell derived from the subject;
(ii) contacting the at least one iPSC-derived cardiomyocyte-like cell with a beta-adrenergic agonist;
(iii) further contacting the at least one iPSC-derived cardiomyocyte-like cell from (ii) with a beta-blocker;
(iv) determining a first Beat Rate Variability (BRV) for the at least one iPSC-derived cardiomyocyte-like cell based on changes in at least one electrophysiological property in the at least one iPSC-derived cardiomyocyte-like cell; and
(v) comparing the first BRV to a second BRV for at least one control.
Beat Rate Variability may be determined using data from the above measurements and using any suitable algorithms and/or software. If the first Beat Rate Variability is lower than the second Beat Rate Variability, this may be indicative of risk of and/or predisposition to cardiac arrhythmia in the subject as compared to a normal individual.
In (v) of the above method, the first Beat Rate Variability may be compared to any suitable control or set of controls in order to determine the severity of the risk and/or predisposition to cardiac arrhythmia in the subject. For example, at least one control comprising at least one iPSC-derived cardiomyocyte-like cell derived from an individual may be used. The individual may be a normal individual lacking risk factors for cardiac arrhythmia, or an individual known to have risk factors or known to have cardiac arrhythmia. Other controls may also be used, for example comprising cardiomyocyte(s) from at least one of the abovementioned individuals. HRV measurements of the above individuals may also serve as suitable controls, i.e. the first BRV may be compared to at least one HRV from at least one of the abovementioned individuals. While generally accepted threshold values for declaring a safe boundary indicating normal HRV may not be well established at this point, such values if established in the future may be suitable as controls as well.
When the at least one control comprises at least one iPSC-derived cardiomyocyte-like cell derived from a normal individual, if the first Beat Rate Variability is lower than the second Beat Rate Variability, this may be indicative of risk of and/or predisposition to cardiac arrhythmia in the subject as compared to a normal individual.
In the above method, (iv) may comprise measuring at least one electrophysiological property in the at least one iPSC-derived cardiomyocyte-like cell, the at least one electrophysiological property comprising the power spectral density of beat-to-beat or RR intervals, ECG, blood pressure, ballistocardiograms, the pulse wave signal derived from a photoplethysmograph, field potential duration (FPD), minimum field potential (FPmin), conduction velocity, beating frequency and/or regularity of beating rhythm. The method (at (iv)) may comprise measuring the power spectral density of beat-to-beat or RR intervals in the at least one iPSC-derived cardiomyocyte-like cell. The method (at (iv)) may comprise measuring at least one electrophysiological property in the iPSC-derived cardiomyocyte-like cell(s) after (ii) and after (iii). The iPSC-derived cardiomyocyte-like cell(s) of the method may be derived from human iPSC. Any suitable beta-adrenergic agonist may be used in the method, for example isoprenaline. Any suitable beta-blocker may be used in the method, for example propranolol, atenolol.
Further, the invention also relates to Induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell(s) for use in a method for predicting risk of and/or predisposition to cardiac arrhythmia in a subject according to any aspect of the invention. The invention also includes a kit comprising these induced pluripotent stem cell (iPSC)-derived cardiomyocyte-like cell(s).
It is understood that the method for predicting risk of and/or predisposition to cardiac arrhythmia in a subject is an in vitro method.
Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention.
In a proof of principle study, the effects of various agents including four classes of anti-arrhythmic drugs classified according to the Vaughan Williams system and beta blockers were assessed using hiPSC-CMs as an in vitro model.
The US Food and Drug Administration (FDA) defined prolongation of QT interval on an ECG as a major drug safety issue. Consistently, assessing risk for QT interval prolongation is part of the standard preclinical evaluation of New Chemical Entities (NCEs) as defined by the International Conference of Harmonization (ICH) Expert Working Group in topic S7B for all drugs in development. QT prolongation tracks cardiac repolarization reserve and is an indicator for increased risk of torsade de pointes (TdP), a life threatening polymorphic ventricular tachycardia. Drug-induced prolongation of QT-interval is often evoked by affecting the rapid potassium current IKr through disruption of hERG ion channel activity. While evaluations of QT interval changes may be a prime requisite, not all drugs may directly interfere with hERG channels. In addition to potassium channels, the electrical activity of a cardiomyocyte is largely dependent on voltage-gated sodium and calcium channels. Whereas activation of sodium channels initiates an action potential, inward Ca2+ currents through (L-type) voltage-gated calcium channels sustain membrane depolarization, but are counterbalanced by outward potassium currents in the repolarization phase to complete a cardiac cycle. Thus, it is also important to evaluate additional phases along with QT interval to generate a comprehensive electrical profile throughout the cardiac cycle.
In this study, various electrophysiological properties of hiPSC-CMs when exposed to the different agents were studied.
Drugs
The following anti-arrhythmic drugs were studied:
Quinidine (Class Ia)
Lidocaine (Class Ib)
Flecainide (Class Ic)
Sotalol (Class II and III)
Amiodarone (Class III with I, II and IV activities)
Verapamil (Class IV)
Nadolol (Class II)
Atenolol (Class II)
Propranolol (Class II)
Cell Lines and Culture
An episomal based method was utilized to reprogram fibroblast as reported previously (Mehta et al., 2011). Human iPSC lines [MSnviPSNF2 (C2), MSnviPSNF3 (C3)] were maintained on 1% matrigel (BD Biosciences, CA, USA) and grown in chemically defined mTeSR1 medium (Stem Cell Technologies, VA, Canada). Care was taken to manually remove the differentiated areas (<10%) with the help of a scraper before passaging. Cells were washed with DMEM-F12 (Invitrogen, USA) and incubated with 1 mg/ml dispase (Sigma, USA) for 5-7 minutes. Cells were then washed with DMEM-F12 and colonies scrapped from the culture dishes. Controlled tituration of the colonies was performed to get small clumps of approximately 50-70 μm in size for replating on new matrigel coated dishes (1:6 split ratio). Cells were fed daily with fresh mTeSR1 medium (StemCell Technologies Inc, VA, Canada) and passaged every 5-6 days and maintained at 37° C. under 5% CO2 in air at 95% humidity.
EB Formation and Cardiomyocyte Differentiation
For example, cardiomyocyte differentiation was performed following EB formation as reported previously (Mehta et al., 2011). Briefly, hiPSCs colonies were dispersed into small clumps and placed in low adhesion culture dishes in EB medium as described previously (Mehta et al., 2010) with 5 μM of SB203580 (Calbiochem, USA) for 8 days. Subsequently, EBs were plated on 0.1% gelatin coated dishes in EB medium without SB203580. Beating areas were typically observed around day 10-12 from EB formation. Beating areas were manually cut after day 21 of differentiation and utilized for various experiments.
Viral free hiPSC-derived cardiomyocytes express hallmark cardiac-specific structural and sarcomeric proteins (actinin, troponins, MYH7, and MLC2v, titin), gap-junction proteins like connexin 43, ion channel proteins [Cav1.3, encoding the α1D subunit of the L-type calcium channel; KCNH2 (hERG), mediating the rapid delayed rectifier potassium current (IKr); and the hyperpolarization-activated cyclic nucleotide-gated potassium channel (HCN2), responsible for the If pacemaker current, SERCA and Na-Ca exchanger] based on gene and protein expressions (Mehta et al., 2011)
Multielectrode Array (MEA) Electrophysiology
To characterize the electrophysiological properties of the hiPSC-CMs, a multielectrode array (MEA) recording system (Multichannel Systems, Reutlingen, Germany) was used. The contracting areas were microdissected and plated on gelatin coated MEA plates. The MEA system allows simultaneous recordings from 60 titanium nitride electrodes (30 μm) at high spatial (200 μm) and temporal (15 kHz) resolutions. To assess the effects of different drugs on the electrophysiological properties, the stock drugs in DMSO were diluted in medium (2 mL). All drugs utilized in the study were purchased from Sigma, USA. Extracellular recording were performed for 180-300 seconds at baseline and at 5 minutes after drug application. The local activation maps were generated using Cardio2D software (Multichannel Systems, Reutlingen, Germany). The recorded electrograms were also used to determine the local field potential (FP) duration (FPD). FPD measurements were normalized (corrected FPD [cFPD]) to the beating rate of the contracting areas with the Bazzet correction formula: cFPD_FPD/√(RR interval) as described previously (Zwi et al ., 2009). Conduction velocity was also determined as described in Zwi et al., (2009).
Beat Rate Variability Analysis in beta-adrenergic response
To study the autonomic modulations of beating period of the contracting EBs, power spectral density of beat-to-beat or RR intervals based on 5-min recordings from the MEA were used to derive the Total Power (TP), very low frequency power (VLF), low frequency power (LF), high frequency power (HF), LF (normalized unit), HF (normalized unit) and ratio of LF/HF of spectral of beat rate variability using software such as HRV Toolkit (physionet.org/tutorials/hrv-toolkit/, Harvard Medical School) or LabVIEW Biomedical Toolkit for heart rate variability. Contracting EBs from normal healthy donor or individual with genetic predisposition to cardiac arrhythmia was exposed to 0.1 μM of isoprenaline and subsequently suppressed with 1 μM beta-blocker (propranolol or atenolol) to study sympathvagal balance. The data were obtained using iPSC-derived cardiomyocyte-like cells from an individual with genetic pre-disposition to cardiac arrhythmia (n=4; referring to 4 regional areas within an EB), and iPSC-derived cardiomyocyte-like cells from a normal individual without genetic pre-disposition to cardiac arrhythmia (n=10).
Statistical Analysis
Comparisons at each time point were conducted using analysis of variance (ANOVA), and all data are presented as mean values±s.e.m of three independent experiments. Differences were considered statistically significant at p≦0.05. Corrected field potential duration curves were fitted using the one phase decay algorithm from GraphPad Prism software. 95% confidence intervals are plotted as dashed lines.
Results
Anti-arrhythmogenic Drug Induced Electrical Alterations in hiPSC-CMs
a) Effects of sodium (Na+) channel blockers on hiPSC-CMs
The effects of clinical drugs that affect Na+ channels on hiPSC-CMs were evaluated. Quinidine (Class Ia) which primarily blocks the fast inward sodium current (INa) but with potassium channel blocking abilities, demonstrated a significant 55% cFPD prolongation at 10 μM dose (
Lidocaine (Class Ib), which blocks Na+ influx through voltage-gated Na+ channels, did not demonstrate any significant changes in cFPD (
Flecainide (Class Ic), which blocks sodium current with slow kinetics, caused 1.7 fold increase in cFPDs at 1 μM concentrations (
b) Effects of beta-blockers on hiPSC-CMs
The effects of two beta-blockers, nadolol and propranolol on the hIPSC-CM clusters were evaluated. Both nadolol and propranolol did not have any significant effects on cFPD from both cell lines (
c) Effects of potassium (K+) channel blockers on hiPSC-CMs
Sotalol (Class II and III) and amiodarone (Class III with I, II and IV activities), both demonstrated prolongation of cFPDs (
d) Effects on calcium (Ca2+) channel blockers on hiPSC-CMs
The effect of verapamil (Class IV), a calcium channel blocker and also a potent hERG blocker, was evaluated. cFPD reduced by 60% following 5 μM verapamil treatment (FIG. 4A,C). Prolonged exposure to verapamil at 5 μM concentration resulted in beating arrest. Furthermore, verapamil also reduced FPmin by 40% and 80% at 1 μM and 5 μM concentrations, respectively (
Drug Induced cFPD Chancres and Clinical Relevance
Alterations in QT interval is one of the critical criteria for drug evaluations on cardiac tissue and the local field potential duration (FPD) of cardiomyocytes reflects the local QT interval (Zwi et al., 2009). Thus, non-linear dose dependent (range 10−9-10−4 M) regression analysis utilizing one phase decay algorithms on normalized cFPD was performed. These regression analyses were overlaid with human estimated unbound therapeutic plasma concentration (ETPC unbound) ranges (
Drug-Induced Arrhythmia
The different agents were also evaluated to determine if these agents (drugs) could induce arrhythmia in hiPSC-CMs at supraphysiological ranges. Human iPSC-CMs were treated with higher (10-100 μM) doses to study their effects on regularity of beating rhythm. Quinidine enhanced beating frequencies by 3-fold at 100 μM (BF: baseline vs 100 μM Q: 0.66±0.06 Hz vs 1.84±0.08 Hz, n=3, p<0.05). Furthermore, there was a significant alteration in the waveforms at 100 μM with resemblance to tachycardia (
Conduction Velocity
The effects of sodium (Na+) channel blockers (quinidine, lidocaine and flecainide) at different doses (range 0.01-10 μM) on conduction velocity were studied. Significant and differential reduction of conduction velocity was observed with the sodium channel blockers examined. While quinidine reduced conduction velocity by 20-25% over the three tested doses (
Beat Rate Variability
The spectral analysis indicated that contracting EBs derived from individual with genetic disposition to arrhythmia has a lower beat rate variability (BRV) in comparison to contracting EBs derived from normal healthy donor whereby TP with isoprenaline: 0.464±0.047 ms2 vs. 0.645±0.001 ms2, p<0.005 and TP with isoprenaline+beta-blocker: 0.345±0.052 ms2 vs. 0.494±0.010 ms2, p<0.01. VLF with isoprenaline: 0.341±0.167 ms2 vs. 0.578±0.002 ms2, p=NS and VLF with isoprenaline+beta-blocker: 0.227±0.078 ms2 vs. 0.403±0.020 ms2, p<0.05. LF with isoprenaline: 0.058±0.043 ms2 vs. 0.050±0.001 ms2, p=NS and LF with isoprenaline+beta-blocker: 0.072±0.078 ms2 vs. 0.068±0.018 ms2, p=NS. HF with isoprenaline: 0.064±0.095 ms2 vs. 0.017±0.002 ms2, p=NS and HF with isoprenaline+beta-blocker: 0.045±0.043 ms2 vs. 0.022±0.012 ms2, p=NS. LF (normalized unit) with isoprenaline: 61.136±16.674% vs. 74.505±2.380%, p=NS and LF (normalized unit) with isoprenaline+beta-blocker: 63.009±11.372% vs. 76.711±5.109%, p<0.01. HF (normalized unit) with isoprenaline: 38.864±16.674% vs. 25.494±2.381%, p=NS and HF (normalized unit) with isoprenaline+beta-blocker: 36.990±11.372% vs. 23.289±5.109%, p<0.01. LF/HF ratio with isoprenaline: 1.897±1.052 vs. 2.949±0.326, p=NS and LF/HF ratio with isoprenaline+beta-blocker: 1.866±0.711 vs. 3.459±0.847, p<0.01. Such overall reduced BRV in contracting EBs from individual with genetic disposition to arrhythmia is consistent with clinical observations of association of increased arrhythmia and sudden cardiac death with reduced HRV (Lombardi et al 2001).
Discussion
Three subclasses of Class I anti-arrhythmic drugs, quinidine (Class Ia), lidocaine (Class Ib) and flecainide (Class Ic) on the electrophysiological properties of hiPSC-CMs were evaluated. Quinindine and lidocaine both demonstrated significant reduced FPmin values that reflect their expected effects on Na channels. However, quinidine also demonstrated significant prolongation of cFPDs at doses that were within the ETPC unbound range (0.9-32 μM), whereas lidocaine did not cause any cFPD prolongation. The delayed repolarization effect on cFPD prolongation with quinidine may be attributed to its highly complex mode of action that involves multiple channels, including hERG. Consistently, concentration-dose inhibition curves for hERG/IKr, APD90 and QT prolongation by quinidine were known to be tightly correlated (Redfern et al., 2003). Furthermore, quinidine is utilized clinically to modulate QT in rhythm management, though with considerable proarrhythmic risks. Furthermore, the results demonstrated tachycardia-like arrhythmia at high doses demonstrating considerable risk associated with quinidine. In contrast, amiodarone which has excellent safety profile clinically, such proarrhythmic risk was not observed, even at supraphysiologically elevated dosage.
Interestingly, flecainide (Class Ic) was observed to cause a significant increase in cFPDs within the ETPC unbound range (500-900 μM) and at higher doses, arrhythmias with bigeminy/trigeminy-like waveforms were observed (10 μM). Although, flecainide is widely used to supress atrial fibrillation, it is associated with an increased risk of ventricular proarrhythmia. This could be due to the putative differential effects of flecainide on atrial and ventricular IK1, could account for the selective prolongation of cFPDs and arrhythmia. Initial patch clamp studies have shown that these hiPSC-CM clusters have about 75% ventricular cells and about 20-25% atrial cells The presence of artial population within these clusters may contribute to the initial cFPD prolongation and later at higher doses (1-10 μM) would block hERG channels (IC50>3 μM, Redfern et al., 2003) in both cell types leading to arrhythmias.
Consistent with earlier published reports (Yookoo et al., 2009), both nadolol and propranolol significantly suppressed beating frequency in the presence of isoprenaline. However, in contrary to clinical observations, modulation of beating rates was not apparent when either beta-blocker was applied alone. Furthermore, there was no significant cFPD prolongation within the ETPC unbound range with either of the drug (nadolol: 0.18-0.80 μM, propranodolol: 0.06-0.45 μM).
Although both sotalol and amiodarone increased cFPDs, sotalol had no effect on FPmin (Na currents), while only amiodarone showed changes in FPmin levels. Furthermore, cFPD prolongation with sotalol was maximally observed within the ETPC unbound range (1.8-14 μM), amiodarone caused cFPD prolongations only at a much higher levels than ETPC range (0.3-0.5 nM). These results correlated well with the existing clinical observations whereby amiodarone has an excellent safety profile while sotalol is well-known to lengthen repolarization and refractoriness. Consistently, sotalol at higher dose (500 μM) induced early afterdepolarizations (EADs). while amiodarone maintained regular rhythmic contractions even at highest concentration tested. Due to its broad spectrum activities across different ion channels, there has been considerable variability in the reported action of amiodarone in literature. For example, amiodarone has been reported to prolong, shorten or ineffective in APD modifications (reviewed by Kodama et al., (1997). Similarly, some variations in its ability to block Na currents were reported (reviewed by Kodama et al., 1997). cFPD prolongations along with differential FPmin effects on the cardiomycytes derived from the two cell lines (C2 and. C3) were observed, probably indicating towards differential effects of cells towards the drug. However, these changes were only observed in doses far beyond the ETPC range. Such discrepant outcomes may be due to the unique pharmacodynamic/pharmacokinetic characteristics of amiodarone whereby it is metabolized slowly and has a long retention period that warrants a very low prescribed dose. Nevertheless, the most significant cFPD effects of amiodarone were observed at 1 μM which is consistent to its hERG blocking ability (IC50 1 μM).
Verapamil (Class IV) did not demonstrate cFPD prolongation but shortening as clinically. However, these shortenings were observed beyond its ETPC unbound range (25-81 nM). However, the fact that verapamil (Class IV) did not prolong the cFPD is of interest since there is a close margin between its ETPC unbound (25-81 nM) and hERG IC50 (140-830 nM) that would suggest otherwise. It is important to note that for this reason, verapamil has been a classical example for “false positive” in the conventional hERG assay (Braam et al., (2010). Apart from verapamil (Class IV), sotalol is also of interest in this context as hERG assay would not capture QT effects of sotalol at ETPC unbound (1.8-14 μM) as its hERG IC50 is 74 μM. It is noteworthy that effects of both these drugs were captured using the present hiPSC system, which could have been mispredicted with the conventional hERG assay.
In conclusion, the results show that hiPSC-CM effectively capture the electrophysiological properties and pharmaceutical responses of drugs that match clinical observations on QT modulations and arrhythmia. The results also show that while cFPD prolongation could be used as readouts for QT prolongation, FPmin levels provide additional indications on drugs interactions with voltage-gated sodium channel. Furthermore, the results show that different cell line-derived cardiomyocytes may show variations, which may reflect differential drug response within patient cohorts. Moreover, the reduced BRV .of hiPSC-CMs from individual with genetically predisposed arrhythmia further supported the feasibility of using such hiPSC-CMs to prognosticate cardiac arrhythmia.
Importantly, the examined drugs demonstrated dose-response curve that correlated significantly with therapeutic plasma concentrations achieved clinically. Moreover, drug-induced arrhythmia with tachycardia and bigeminy-like waveforms was demonstrated in selective agents at higher doses that are consistent with clinical observations. These results suggest that hiPSC-CMs may be useful for early evaluation of cardioactive drugs and enhance personalized medicine.
Bode and Olejniczak (2002) Fundamental and Clinical Pharmacology 16(2):105-118
Braam et al., (2010) Stem Cell Research (2010) 4:107-116
Cavero and Crumb (2005) Expert Opinion on Drug Safety 4(3):509-30
Kodama et al., (1997), Cardiovascular Research 35:13-29
Lombardi et al., (2001) Cardiovascular research, 50:210-217.
Mehta et al., (2010) Cell Biology International, 34:1021-1031.
Mehta et al., (2011) Cardiovascular research 91:577-589.
Redfern et al., (2003) Cardiovascular Research 58: 32-45.
Yookoo et al., (2009) Biochem Biophys Res Commun. 387:482-8;
Zwi et al., (2009) Circulation 120:1513-1523.
| Number | Date | Country | Kind |
|---|---|---|---|
| 201200530.2 | Jan 2012 | SG | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/SG2013/000029 | 1/21/2013 | WO | 00 | 7/21/2014 |
